
|Podcasts|January 14, 2022
Pharmacy Focus: Psychedelic Pharmacy - Episode 3
Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder
Advertisement
In this episode, Colonel Dallas Hack discussed the development of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder, as well as how his own background led him to this research. In the interview, Hack said he believes a derivative could improve access as well as acceptance of the psychedelic drug.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Denosumab Biosimilars Boncresa and Oziltus for Osteoporosis-, Cancer-Related Bone Loss
2
'Beyond Weight Loss': Emerging Studies Show How GLP-1 Receptor Agonists May Impact Addiction Behaviors
3
New Drug Approach Targets KRAS-Mutant Lung Cancer to Overcome Therapy Resistance
4
Tradipitant Becomes First Treatment Approved for Vomiting Due to Motion Sickness in 4 Decades
5










































































































































































































